In a report released today, Liana Moussatos from Wedbush reiterated a Buy rating on ObsEva SA (OBSV), with a price target of $38. The company’s shares opened today at $12.57.
According to TipRanks.com, Moussatos is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -7.9% and a 32.1% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as BioMarin Pharmaceutical Inc., Allena Pharmaceuticals Inc, and Aquestive Therapeutics Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for ObsEva SA with a $33.60 average price target, a 167.3% upside from current levels. In a report issued on May 28, H.C. Wainwright also reiterated a Buy rating on the stock with a $44 price target.
See today’s analyst top recommended stocks >>
Based on ObsEva SA’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $20.13 million. In comparison, last year the company had a GAAP net loss of $19.81 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
ObsEva SA engages in the development of therapeutic treatments for woman’s reproductive health and pregnancy. It offers biopharmaceutical drugs addressing conditions compromising pregnancy from conception to birth. The company was founded by Ernest Loumaye and André Chollet in November 2012 and is headquartered in Geneva, Switzerland.
